Shire plc to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychological Association Annual Meeting

Published: May 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PHILADELPHIA, May 17, 2013 /PRNewswire/ --

Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented

Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in San Francisco, May 18-22. The data being presented represent Shire's ongoing commitment to the clinical research of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) and INTUNIV® (guanfacine) Extended-Release Tablets, its approved prescription medicines for Attention-Deficit/Hy??peractivity Disorder (ADHD).

Help employers find you! Check out all the jobs and post your resume.

Back to news